Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
土曜日, 8 29

Quest Diagnostics Inc

DGXNYSE
Trade with Public
Trade with Public
$242.76
-1.85-0.76%
近くで: Aug 28, 5:00 PM EST
$242.76
N/A
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Quest Diagnostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quest Diagnostics (DGX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

7Buy
8Hold
Consensus RatingNeutral# Analysts15Avg. Consensus PT$212Upside to Avg. PT-12.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 28, 2026JP MorganLisa GillPT RaiseNeutral$220→$250
Jul 24, 2026UBSKevin CaliendoPT RaiseNeutral$220→$232
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
Benzinga Newsdesk

PRO
Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved